Tonix Pharmaceuticals Holding Corporation (TNXP) 시세

I may have picked up 30,000 shares+ today. We are going to the moon.

never know . watching

We finally closed above the 50 dma. It's got some running room now.

TNXP: Soaring in the Post-Market, right now. (See below what COPILOT as to say about it.)

"Why is TNXP stock soaring by 68% in the Post-M right now, 11-19-24? Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock is soaring today due to positive investor sentiment ahead of their Chief Operating Officer, Jessica Morris, presenting at the Winter 2024 Investor Summit. This event is generating excitement and optimism among investors about the company's future prospects1. Additionally, Tonix Pharmaceuticals has been making significant strides in its product pipeline, including the development of TNX-102 SL for fibromyalgia and TNX-4200 for antiviral treatments. These advancements are likely contributing to the stock's surge. Are you considering investing in TNXP, or are you just curious about the recent developments?"
https://www.tonixpharma.com/jessica-edgar-morris/
/////////////////////////////////////////////////////////////////////////////////////////

TNXP......................https://stockcharts.com/h-sc/ui?s=TNXP&p=W&b=5&g=0&id=p86431144783

Less than 30 days now left in the 60 day window for the fda to
decide whether or not to accept their NDA submission.

The 'story' has been told, its out there. And a lot of shares are being
'churned' on a daily basis. Got 6 MILLION already today in volume for example.

Don't think the 'story' is going to do very much at this point.

Think the only way this thing gets off the 'floor' so to speak is for the 'approval' cycle to
commence. And the first step is their NDA being 'accepted' for review.

disclaimer: own shares, APS around 17.5 cents... 50 cents is my first target price based on
acceptance of the submission.. (although won't be surprised if it takes some months leading up
a PDUFA day IF they get one)

This could give us a bump up.
https://www.nasdaq.com/press-release/tonix-pharmaceuticals-present-winter-2024-investor-summit-virtual-2024-11-18

I am going with 50 cents IF their NDA is 'accepted' by the fda. Believe thats now down to
around 30 days left in the standard 60 day window post submission.

Then given the share count outstanding (somewhere around 140 Million shares/$18 Mil MARKET CAP),
looking for around $3/sh IF approved (Market Cap: $420 Million)...

And also expecting a REVERSE SPLIT down the road simply to reduce the share count and jack up the
share price over $5 to help draw in the bigger investors.. But thats likely down the road closer to the
approval date when that can help hold up the share price.

Good luck

disclaimer: own shares, plan to add more, but not until this starts to show renewed interest for the shares.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1430306/000183988224038453/tnxp-8k_110824.htm
TNX-1700 (hTFF2-HSA) appears to be a very promising candidate for the treatment of gastric and colorectal cancer, with an innovative mechanism of action that addresses immune inhibition in the tumor microenvironment. The synergy with immune checkpoint inhibitors, favorable preclinical results and the blood-life prolongation approach through fusion with albumin suggest that this drug could represent an effective new therapeutic option, particularly for patients who do not respond to conventional treatments.
Dr. Timothy Wang leading the research, increasing credibility and the possibility of long-term success.
Innovative mechanism of action:
Reduce immune inhibition in the tumor microenvironment (TME), in particular by reducing MDSCs (myeloid-derived suppressor cells) that prevent the effectiveness of immune responses against the tumor.
Synergy with immune checkpoint inhibitors (anti-PD-1):
Greater combined efficacy: TNX-1700 enhances the immune response when combined with anti-PD-1 drugs, as shown in preclinical models of colorectal and gastric cancers.
Promising preclinical evidence:
Robust data in animal models of orthotopic and metastatic tumors showing significant reduction in tumor growth, metastasis and improved survival.
Increased tumor-infiltrating CD8+ T cells, suggesting an improved immune response.
Albumin technology for blood life extension:
Fusion with albumin increases the pharmacokinetics of the drug, reducing the frequency of administration and improving the duration of the therapeutic effect.
it's all nice… very large market! but it takes a lot of money to approve it! maybe in another 7 R/S

If not more of a pop in sp .

This has a good chance at a $20 to $30 pop next year IF FDA approves the "The US Food and Drug Administration (FDA) has granted Fast Track designation to Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia." gets a green light for sales. At this current price of .1427, to me it's worth the risk.just For that.
" https://www.proactiveinvestors.co.uk/companies/news/1059401/tonix-pharmaceuticals-ceo-discusses-new-drug-application-for-fibromyalgia-treatment-1059401.html " Not to mention the DoD military contract and with the pending NATO war with russia and the situation in Asia, " https://finance.yahoo.com/news/tonix-pharmaceuticals-receives-first-contract-120000292.html " And the monkey pox vaccine trials initiative " https://ir.tonixpharma.com/news-events/press-releases/detail/1530/tonix-pharmaceuticals-presented-data-on-potential-mpox " " https://www.tonixpharma.com/pipeline-2/ "

Gobble. Gobble

Pretty big 'market' for a treatment that 'works'. That has a 'need' for one
that works. Never realized how big a problem fibromyalgia 'is'..

https://www.fmaware.org/fibromyalgia-the-economic-burden/#:~:text=Prominent%20fibromyalgia%20researchers%20and%20specialists%20estimate%20the%20costs,loss%20of%201-2%25%20of%20the%20nation%C3%A2%E2%82%AC%E2%84%A2s%20overall%20productivity.

Fibromyalgia: the Economic Burden
The cost of fibromyalgia to both the individual and to society is extensive. A 2007 study found that 34% of fibromyalgia patients spend between $100- $1,000 per month above their insurance to see a healthcare professional. Prominent fibromyalgia researchers and specialists estimate the costs in the U.S. between $12-14 billion each year and accounts for a loss of 1-2% of the nation’s overall productivity.

Looks like it’s ready to go back up again,I am watching the shares to borrow closely,when they start dropping it will start ripping again

good point

YOU ARE ON RIGHT TRACK.

Looking at the 3 Clinical Trials to see what 'happened'..

The one that ended in 2020 passed based on the end points.

The 2nd trial, RALLY, that followed did NOT meet the end points and I wanted to know
WHY it didn't, WHY it failed. At this link is an explanation for why it didn't pass. And tho
it didn't 'pass' cause of 'adverse' effects (see the write up for their explanation), they did state
that the results were otherwise 'consistent' with the first trial results.

https://ir.tonixpharma.com/news-events/press-releases/detail/1304/tonix-pharmaceuticals-announces-phase-3-rally-study-results

So they then started the RESILIENT trial that then passed.

So to sum it up, they ran 3 trials that based on their analysis met the trial endpoints with enough
stat significance to pass, and warrant their NDA submission that just took place. So given this, it
would APPEAR that this should be enough for the fda to accept the submission for review. The only
question that remains at this point is, was the trial 'robust' enough for the fda to say, we agree with the data
that the development does achieve its goal, that it helps people.

TBD'd.. NOTE: this review of the trials, the outcome was my priority when I had a chance even tho
I had already bought shares based on what I initially read. After what just happened to another favorite
of mine (ATNM where the fda concured in trial passed, but they screwed the company over by saying, for
reasons, you now have to run another PH 3 despite the evidence that the development WORKS/HELPS people)
I no longer can trust the trial results even if they are really good, to be 'good' enough anymore..

disclaimer: own shares

Real question is, is it an 'opportunity' in the making??

Not the first time I have bottom 'fed' something that got
pounded down, but had POTENTIAL to rise from the ashes..

Yes, a R/S (1-32 if memory serves me right)
was done in June/July...

Reportedly only around 22 Mil shares in the float. Pretty
tough to do a r/spilt on that..

recent move, Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
10/17/2024 08:00:00 AM

DOWNER, BIGTIME



[-chart]www.stockscores.com/chart.asp?TickerSymbol=TNXP&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]

I THINK A REVERSE SPLIT. Tonix Pharmaceuticals Holding Corp

I THINK DONE BEFORE.

Financials, shares outstanding...Market cap..

OK, like a lot of baby bios with an idea they are trying to push
across the finish line, they are financially strapped for cash. So
even if the fda accepts their NDA, expecting them to do a few more
secondarys/ATMs to raise cash (ie, dilution). But it is an evil
necessity and long term its impact will be on the target price it might
eventually get.

Shares outstanding: see on Yahoo its 22 Mil in the FLOAT, but 140 Mil
'authorized' (available for use in an ATM??)

Market Cap: at least its 'reasonable' vs way overvalued.

Care to enlighten on the point you might be trying to make?
Thanks.

Cause myself for example, am focused on whats possible going forward..
Whats already happened has the share price sub 20 cents.

and the END of the chart that shows a little 'activity' taking place hinting that
maybe the sell off has run its course..

Figure IF the fda accepts their NDA for consideration? The news is bound to
get someones attention.. Thats the first hurdle to overcome..

When it comes to 'luck', I agree, I don't like
to RELY on it being the reason something
goes 'right'..

But in this world called the market, and many facets of life??
Too many things we can't control or forsee coming at us
when we least expect it.

Often, we lack enough information to do anything but
make an educated guess. And its that lack of info
that ends up biting us..

disclaimer: own shares....

Thanks for the info,good skill to you!!
(I don’t believe in luck

From what I can tell, the 1st trial was 'good', then there was a 2nd one that didn't pass, then there was this
3rd one. As for the results, if they say they were good or bad or whatever, I trust them to be honest cause the
results have a criteria they have to be judged against. And while lying is good to bounce the share price, its
not going to get them thru the fda.

But the question is, will the fda accept the trial that was run, the results the independent lab claimed they observed/documented.??

I had a company that ran an fda 'accepted' trial, passed with flying colors. Submitted it to the fda only to have the fda say, the TRIAL wasn't
'good' enough and they have to do another one. Killed the share price from $7 to sub $2 instantly.

And the sad part is, still not sure why the trial wasn't 'good' enough, and why if it wasn't, why the fda accepted it being run in the first place.
Not to mention, there is no doubt about the effectiveness of ATNMs development.

Good luck, added more this morn down around 18 cents.. Next add for consideration is around 20 cents... (let some gains build up, add
smaller lots of shares)

Not sure why 2 trials,wouldn’t want to speculate,results stated positive,I didn’t look for details,maybe an official report is coming?

Good buys... around a 30% return from the 13 cents range.. nice..

Got to do some DD this weekend, see if I can figure out a timeline, and get a better
read on the trials, WHY 2 of them (??). Plus what did the PH 2 show in terms of
'results'..

That will dictate just how heavy I decide to get on this one..

Good luck

My first in was low .13s,made a few trades so far,chart prediction has been good so far,no rug pulls at least lol

Stumbled across this one thanks to a tip from someone
asking me to 'check it out'.

Have to say, liked what I read, especially that someone with a position
decided to grab some more shares. Figured they had a reason to get their
initial ones, and still believe enough to grab some more.

Plus the trials, only question is, are they 'robust' enough to satisfy the fdas threshold..

And the chart is also indicating, the bottoming activity may have reached an end point,
maybe time to creep a bit higher..

Good luck.

FDA,Fast track,2 phase 3 studies with good results,approval expected !!

72k watchers,volume up 50%,zero borrow,they letting it move now so could see some quick moves

Hitting nhod’s during death hour is an insane good sign of strength

Anyone else here getting scammer calls from people who sound like they are south Asia wanting your proxy vote for this company over the phone and asking for your info ?

TNXP.....................................https://stockcharts.com/h-sc/ui?s=TNXP&p=W&b=5&g=0&id=p86431144783

New patent expected to provide market exclusivity into 2036
https://www.wallstreetreporter.com/2024/09/27/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-covering-the-subcutaneous-delivery-of-fda-approved-zembrace-symtouch-to-treat-migraines/
Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults

CHATHAM, N.J., Sept. 27, 2024 — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,097,183 to the Company on September 24, 2024. The patent, entitled “Pharmaceutical Composition for Treating Migraine”, claims use of a pre-filled autoinjector comprising a composition of Zembrace® SymTouch® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to provide protection into 2036.

“We are excited to announce the issuance of this additional patent, providing additional protection for our exclusive marketing and sale of FDA-approved Zembrace® for the treatment of migraines,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We believe Zembrace® is a compelling non-oral option for people who suffer with migraines.”

Tonix recently launched a new educational campaign, “Does Your Migraine Pill Work Every Time?” The goal of the campaign is to educate patients and their healthcare providers on the benefits of non-oral migraine medications including nasal and injectable treatment options. Non-oral migraine medications, such as injectables and nasal sprays, do not rely on the digestive system to be absorbed and can offer the potential for faster relief from migraine symptoms in as little as 10 minutes.

Migraine often requires patients to advocate for themselves to develop an effective migraine treatment plan. Empowering patients to understand why they are experiencing delayed or inconsistent relief from oral medications and educating them on other migraine treatment options could ultimately improve their management of migraine symptoms and ultimately enhance their quality of life.

For example, gastroparesis is common before, during, and sometimes in between migraine attacks. Gastroparesis can slow or even block the absorption of oral medications causing delayed, incomplete, or no migraine symptom relief. Tonix will launch a new disease education website, www.gpmigraine.com, for patients who want to learn more about gastroparesis and migraine and why their oral medications do not work.

Dr. Lederman continued, “Tonix is dedicated to educating patients and their healthcare providers on gastroparesis and how non-oral medicines including nasal and injectable medications can help patients manage their migraines. We hope to inspire patients to optimize their migraine treatment plan with non-oral medications.”

About Migraine

Nearly 40 million people in the United States suffer from migraine1 and it has been recognized as the second leading cause of disability in the world2,3. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity often associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia)4.

1Law, H. Z., Chung, M. H., Nissan, G., Janis, J. E., & Amirlak, B. (2020). Hospital Burden of Migraine in United States Adults: A 15-year National Inpatient Sample Analysis. Plastic and reconstructive surgery. Global open, 8(4), e2790. https://doi.org/10.1097/GOX.0000000000002790

2GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954-976.

3Steiner, T.J., Stovner, L.J., Jensen, R. et al. Lifting the Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21, 137 (2020).

4Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to submit a New Drug Application (NDA) to the FDA in October 2024 for TNX-102 SL, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced the U.S. Department of Defense (DoD), Defense Threat Reduction Agency (DTRA) awarded it a contract for up to $34 million over five years in an Other Transaction Agreement (OTA) to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD, instrumental in progressing this development. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.


*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at http://www.tonixpharma.com.

TNXP
Tonix Pharmaceuticals Holding Corporation
0.1444
0.0078 (5.71%)
Volume: 205,307,529
Day Range: 0.1434 - 0.2124
Last Trade Time: 4:25:57 PM EDT

Index - P/E - EPS (ttm) -22.15 Insider Own 0.00% Shs Outstand 137.26M Perf Week -1.02%
Market Cap 20.04M Forward P/E - EPS next Y -10.45 Insider Trans - Shs Float 137.25M Perf Month -51.37%
Income -149.01M PEG - EPS next Q -2.93 Inst Own 0.51% Short Float 0.34% Perf Quarter -79.07%
Sales 12.46M P/S 1.61 EPS this Y 47.76% Inst Trans 118.70% Short Ratio 0.02 Perf Half Y -97.55%
Book/sh 4.28 P/B 0.03 EPS next Y 27.29% ROA -129.55% Short Interest 0.47M Perf Year -99.38%
Cash/sh 0.03 P/C 4.82 EPS next 5Y - ROE -163.24% 52W Range 0.13 - 26.56 Perf YTD -98.87%
Dividend Est. - P/FCF - EPS past 5Y 79.31% ROI -308.74% 52W High -99.45% Beta 2.09
Dividend TTM - Quick Ratio 0.72 Sales past 5Y 0.00% Gross Margin -17.61% 52W Low 12.31% ATR (14) 0.04
Dividend Ex-Date - Current Ratio 1.15 EPS Y/Y TTM -61.43% Oper. Margin -764.06% RSI (14) 27.27 Volatility 5.23% 13.99%
Employees 103 Debt/Eq 0.22 Sales Y/Y TTM - Profit Margin -1196.11% Recom 1.00 Target Price 21.00
Option/Short No / Yes LT Debt/Eq 0.15 EPS Q/Q -619.99% Payout - Rel Volume 9.63 Prev Close 0.14
Sales Surprise -36.91% EPS Surprise -489.01% Sales Q/Q - Earnings Aug 19 BMO Avg Volume 21.38M Price 0.15
SMA20 -8.04% SMA50 -57.91% SMA200 -97.51% Trades Volume 206,017,682 Change 6.88%



Date Action Analyst Rating Change Price Target Change
Apr-18-22 Initiated Noble Capital Markets Outperform
Apr-18-19 Upgrade ROTH Capital Neutral ? Buy $4
Aug-18-17 Upgrade ROTH Capital Neutral ? Buy $6
Sep-07-16 Downgrade ROTH Capital Buy ? Neutral
Feb-17-16 Reiterated Oppenheimer Outperform $18 ? $10
Nov-04-15 Initiated Cantor Fitzgerald Buy
Jun-12-15 Initiated Oppenheimer Outperform $18
Feb-17-15 Reiterated ROTH Capital Buy $10 ? $12
Sep-29-14 Reiterated ROTH Capital Buy $17 ? $10

Today 07:00AM
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines
(GlobeNewswire)
+6.88%
Sep-23-24 07:00AM
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024)
(GlobeNewswire)
-8.54%
Sep-19-24 07:00AM
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
(GlobeNewswire)
Sep-18-24 07:30AM
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
(ACCESSWIRE)
Sep-16-24 07:00AM
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
(GlobeNewswire)
-5.93%
01:00PM
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Finviz Elite
Sep-11-24 01:00PM
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
(ACCESSWIRE)
Sep-10-24 07:00AM
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations
(GlobeNewswire)
-6.12%
Sep-09-24 07:00AM
Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Talk at Immunology Symposium at the University of Alberta
(GlobeNewswire)
+15.86%
Sep-06-24 07:00AM
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
(GlobeNewswire)
-10.26%
Sep-04-24 07:00AM
As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL
(ACCESSWIRE)
Aug-29-24 07:00AM
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-14.82%
Aug-28-24 07:00AM
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-17.37%
Aug-26-24 10:41AM
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
(Benzinga)
+10.00%
07:00AM
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801
(GlobeNewswire)
Aug-23-24 07:45AM
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
(ACCESSWIRE)
07:00AM
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Finviz Elite
Aug-21-24 07:00AM
Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
(GlobeNewswire)
-5.26%
Aug-20-24 12:34PM
Tonix initiates Phase II trial for emergency cocaine intoxication treatment
(Clinical Trials Arena)
-14.61%
07:00AM
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
(GlobeNewswire)
Aug-19-24 06:00AM
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire)
Aug-16-24 10:52PM
TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
(InvestorPlace)
01:29PM
Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
(Benzinga)
07:00AM
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
(GlobeNewswire)
Aug-13-24 08:00AM
Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
(GlobeNewswire)
Aug-12-24 08:00AM
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
(GlobeNewswire)
+7.00%
Aug-06-24 08:00AM
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company's Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
(GlobeNewswire)
Aug-01-24 07:45AM
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
(ACCESSWIRE)
Jul-31-24 08:00AM
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya
(GlobeNewswire)
-12.23%
Jul-30-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
(GlobeNewswire)
Jul-29-24 09:00AM
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
(PR Newswire)
Jul-25-24 08:30AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
(GlobeNewswire)
+9.96%
08:00AM
Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.
Finviz Elite
08:00AM
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia
(GlobeNewswire)
Jul-24-24 07:45AM
Beyond 'One Bug, One Drug' - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
(ACCESSWIRE)
-7.19%
Jul-22-24 07:00AM
7 Sorry Biotech Stocks Set to Make Investors Sad
(InvestorPlace)
Jul-19-24 12:48PM
Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence
(News Direct)
Jul-18-24 10:20AM
Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya for fibromyalgia management
(News Direct)
Jul-17-24 08:00AM
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
(ACCESSWIRE)
Jul-10-24 04:30PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
Jul-09-24 09:15AM
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
(GlobeNewswire)
-15.47%
07:39AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
Jul-08-24 05:00PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
-10.96%
08:00AM
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
07:00AM
7 F-Rated Stocks To Sell in July
(InvestorPlace)
Jul-01-24 11:07AM
Nano-Cap Tonix Pharmaceuticals Secures Large US Department of Defense Contract
(Benzinga)
08:00AM
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
(GlobeNewswire)
Jun-28-24 04:05PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
Jun-27-24 11:01AM
AMZN Stock Alert: Amazon Just Joined the $2 Trillion Club
(InvestorPlace)
-38.67%
08:37AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
(InvestorPlace)
08:36AM
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
(GlobeNewswire)
07:34AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
(InvestorPlace)
Jun-26-24 04:40PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
-10.00%
03:13PM
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Jun-25-24 08:00AM
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
(GlobeNewswire)
+5.04%
Jun-21-24 07:30AM
7 F-Rated Penny Stocks to Avoid This June
(InvestorPlace)
Jun-20-24 08:00AM
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
+10.66%
Jun-18-24 12:31PM
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
(InvestorPlace)
+8.93%
08:00AM
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
(GlobeNewswire)
Jun-17-24 08:00AM
Tonix Pharmaceuticals Presented Poster of Tonmya for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
(GlobeNewswire)
Jun-13-24 05:00PM
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
(GlobeNewswire)
+5.50%
Jun-12-24 10:06AM
FedEx Layoffs 2024: What to Know About the Latest FDX Job Cuts
(InvestorPlace)
-47.89%
09:00AM
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
(GlobeNewswire)
08:52AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today?
(InvestorPlace)
07:46AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
(InvestorPlace)
Jun-11-24 05:17PM
Tonix Pharmaceuticals Announces Proposed Public Offering
(GlobeNewswire)
10:26AM
Tonix Pharmaceuticals Nears Market Entry with Tonmya for Fibromyalgia Management
(News Direct)
Jun-10-24 12:14PM
SOUN Stock Alert: SoundHound AI Pays Off Debt Early
(InvestorPlace)
-33.66%
11:55AM
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
(InvestorPlace)
Jun-06-24 11:00AM
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
(GlobeNewswire)
-28.04%
08:00AM
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
(GlobeNewswire)
Jun-05-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
(GlobeNewswire)
Jun-03-24 08:00AM
Tonix Pharmaceuticals Presented New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting
(GlobeNewswire)
May-30-24 08:00AM
Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting
(GlobeNewswire)
May-29-24 08:00AM
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
(GlobeNewswire)
May-28-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
(GlobeNewswire)
May-22-24 08:00AM
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
(GlobeNewswire)
May-21-24 08:00AM
Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
May-20-24 10:53AM
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace)
May-15-24 08:00AM
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
(GlobeNewswire)
May-13-24 04:30PM
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire)
+5.20%
Apr-29-24 09:00AM
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
(ACCESSWIRE)
+6.53%
Apr-24-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
(GlobeNewswire)
Apr-09-24 06:31AM
3 Biotech Stocks to Dump Before They Go to Zero
(InvestorPlace)
Apr-01-24 04:15PM
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
(GlobeNewswire)
Mar-28-24 09:32AM
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
(GlobeNewswire)
-43.10%
Mar-25-24 08:00AM
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
(GlobeNewswire)
-5.20%
Mar-24-24 04:05PM
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
(InvestorPlace)
Mar-21-24 08:00AM
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
(GlobeNewswire)
Mar-20-24 08:00AM
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
Mar-19-24 08:00AM
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
(GlobeNewswire)
Mar-12-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
(GlobeNewswire)
-8.86%
Mar-11-24 08:00AM
Tonix Pharmaceuticals Reports Improvement in Brain Fog, in Fibromyalgia Patients Treated with Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
(GlobeNewswire)
Mar-07-24 09:37AM
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
(GlobeNewswire)
08:00AM
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
(GlobeNewswire)
Mar-06-24 08:00AM
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia
(GlobeNewswire)
Mar-05-24 08:00AM
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
(GlobeNewswire)
Feb-29-24 08:00AM
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
(GlobeNewswire)
Feb-28-24 08:00AM
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
(GlobeNewswire)
06:56AM
Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial
(News Direct)
06:54AM
Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation
(News Direct)
Feb-27-24 08:00AM
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya to Support Development and Partnering in Japan and China
(GlobeNewswire)
+6.88%
Feb-26-24 08:00AM
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
(ACCESSWIRE)
+6.93%


Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Income Statement • Balance Sheet • Cash Flow
Data


YoY Growth

YoY Growth %
Timeframe


Annual

Quarterly
Period End Date TTM 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Period Length 12 Months 12 Months 12 Months
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
12.46 7.77 0.00
Cost of Goods Sold Incl. D&A
14.65 9.03 1.25
Gross Profit
-2.19 -1.26 -1.25
Selling, General and Administrative Excl. Other
92.99 117.12 110.84
Research and Development
60.73 86.66 81.88
Other Operating Expense
0.00 0.00 0.00
Operating Income
-95.19 -118.38 -112.09
Interest Expense
0.00
Unusual Expense
52.81 -0.30 0.00
Net Income Before Taxes
-149.01 -116.66 -110.22
Income Taxes
0.00 0.00 0.00
Consolidated Net Income
-149.01 -116.66 -110.22
Net Income From Continuing Operations
-149.01 -116.66 -110.22
Net Income
-149.01 -116.66 -116.88
EPS (Recurring)
-27.43 -6.86 -20.44
EPS (Basic, Before Extraordinaries)
-22.15 -6.85 -20.44
EPS (Diluted)
-22.15 -6.85 -20.44
EBITDA
-90.30 -114.09 -110.84
Price To Earnings Ratio
-0.01 -0.01 -1.15
Price To Sales Ratio
0.23 0.88
Gross Margin
-17.61 -16.27
Operating Margin
-764.06 -764.06 -3,103.01
Net Margin
-1,196.11 -1,501.78
Shares Outstanding
9.83 58.61 12.24
Market Capitalization
18.75 18.75 755.89
values in Millions, USD

open in yahoo
|
open in reuters
|
open in marketwatch
|
open in google
|
open in EDGAR

affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.

TNXP: But the FLOAT is still way too HUUUUUUUUGE. (Maybe better if they "BUY-BACK" 100-million shares.)

$0.15 plus shares 10 mil buyback ????? then retire them ????? this could hit $1.50 soon.

who these gents ?????

Tonix Pharma brothers RNAZ

92,000 plus trades \\// TNXP
Tonix Pharmaceuticals Holding Corporation
0.1582
0.0216 (15.81%)
Volume: 162,549,936
Day Range: 0.1434 - 0.2124
Bid: 0.1581
Ask: 0.1583
Last Trade Time: 10:49:38 AM EDT
Total Trades: 92,437

pps spike early morn but retreats some.

worth some lunch money $TNXP

https://www.otcmarkets.com/filing/html?id=17860369&guid=kDL-kFxAigxpJth

TNXP..........................................https://stockcharts.com/h-sc/ui?s=TNXP&p=W&b=5&g=0&id=p86431144783

TNXP: I grabbed some early, but the FLOAT here is worrisome --- unless they do a healthy REVERSE SPLIT soon, before RS's go out of 'fashion'!!

TNXP: Hopefully, TNXP announces soon a nice, big, fat, REVERSE SPLIT --- to send it really SOARING in price!!! (RS's are the latest RAGE, ya know!!)